Cargando…

Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors

Under endoplasmic reticulum (ER) stress, unfolded proteins accumulate in the ER to activate the ER transmembrane kinase/endoribonuclease (RNase)—IRE1α. IRE1α oligomerizes, autophosphorylates, and initiates splicing of XBP1 mRNA, thus triggering the unfolded protein response (UPR). Here we show that...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Likun, Perera, B. Gayani K., Hari, Sanjay B., Bhhatarai, Barun, Backes, Bradley J., Seeliger, Markus A., Schürer, Stephan C., Oakes, Scott A., Papa, Feroz R., Maly, Dustin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508346/
https://www.ncbi.nlm.nih.gov/pubmed/23086298
http://dx.doi.org/10.1038/nchembio.1094
_version_ 1782251190308831232
author Wang, Likun
Perera, B. Gayani K.
Hari, Sanjay B.
Bhhatarai, Barun
Backes, Bradley J.
Seeliger, Markus A.
Schürer, Stephan C.
Oakes, Scott A.
Papa, Feroz R.
Maly, Dustin J.
author_facet Wang, Likun
Perera, B. Gayani K.
Hari, Sanjay B.
Bhhatarai, Barun
Backes, Bradley J.
Seeliger, Markus A.
Schürer, Stephan C.
Oakes, Scott A.
Papa, Feroz R.
Maly, Dustin J.
author_sort Wang, Likun
collection PubMed
description Under endoplasmic reticulum (ER) stress, unfolded proteins accumulate in the ER to activate the ER transmembrane kinase/endoribonuclease (RNase)—IRE1α. IRE1α oligomerizes, autophosphorylates, and initiates splicing of XBP1 mRNA, thus triggering the unfolded protein response (UPR). Here we show that IRE1α’s kinase-controlled RNase can be regulated in two distinct modes with kinase inhibitors: one class of ligands occupy IRE1α’s kinase ATP-binding site to activate RNase-mediated XBP1 mRNA splicing even without upstream ER stress, while a second class can inhibit the RNase through the same ATP-binding site, even under ER stress. Thus, alternative kinase conformations stabilized by distinct classes of ATP-competitive inhibitors can cause allosteric switching of IRE1α’s RNase—either on or off. As dysregulation of the UPR has been implicated in a variety of cell degenerative and neoplastic disorders, small molecule control over IRE1α should advance efforts to understand the UPR’s role in pathophysiology and to develop drugs for ER stress-related diseases.
format Online
Article
Text
id pubmed-3508346
institution National Center for Biotechnology Information
language English
publishDate 2012
record_format MEDLINE/PubMed
spelling pubmed-35083462013-06-01 Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors Wang, Likun Perera, B. Gayani K. Hari, Sanjay B. Bhhatarai, Barun Backes, Bradley J. Seeliger, Markus A. Schürer, Stephan C. Oakes, Scott A. Papa, Feroz R. Maly, Dustin J. Nat Chem Biol Article Under endoplasmic reticulum (ER) stress, unfolded proteins accumulate in the ER to activate the ER transmembrane kinase/endoribonuclease (RNase)—IRE1α. IRE1α oligomerizes, autophosphorylates, and initiates splicing of XBP1 mRNA, thus triggering the unfolded protein response (UPR). Here we show that IRE1α’s kinase-controlled RNase can be regulated in two distinct modes with kinase inhibitors: one class of ligands occupy IRE1α’s kinase ATP-binding site to activate RNase-mediated XBP1 mRNA splicing even without upstream ER stress, while a second class can inhibit the RNase through the same ATP-binding site, even under ER stress. Thus, alternative kinase conformations stabilized by distinct classes of ATP-competitive inhibitors can cause allosteric switching of IRE1α’s RNase—either on or off. As dysregulation of the UPR has been implicated in a variety of cell degenerative and neoplastic disorders, small molecule control over IRE1α should advance efforts to understand the UPR’s role in pathophysiology and to develop drugs for ER stress-related diseases. 2012-10-21 2012-12 /pmc/articles/PMC3508346/ /pubmed/23086298 http://dx.doi.org/10.1038/nchembio.1094 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Wang, Likun
Perera, B. Gayani K.
Hari, Sanjay B.
Bhhatarai, Barun
Backes, Bradley J.
Seeliger, Markus A.
Schürer, Stephan C.
Oakes, Scott A.
Papa, Feroz R.
Maly, Dustin J.
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
title Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
title_full Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
title_fullStr Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
title_full_unstemmed Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
title_short Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
title_sort divergent allosteric control of the ire1α endoribonuclease using kinase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508346/
https://www.ncbi.nlm.nih.gov/pubmed/23086298
http://dx.doi.org/10.1038/nchembio.1094
work_keys_str_mv AT wanglikun divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT pererabgayanik divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT harisanjayb divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT bhhataraibarun divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT backesbradleyj divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT seeligermarkusa divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT schurerstephanc divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT oakesscotta divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT papaferozr divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors
AT malydustinj divergentallostericcontroloftheire1aendoribonucleaseusingkinaseinhibitors